Peripheral nerve stimulation compared with usual care for pain relief of hemiplegic shoulder pain: a randomized controlled trial.

Peripheral nerve stimulation compared with usual care for pain relief of hemiplegic shoulder pain: a randomized controlled trial.
复制标题

DOI:
10.1097/phm.0000000000000011
复制
发表时间:
2014-01
影响因子:
3
通讯作者:
Chae J
Chae J
中科院分区:
医学3区
文献类型:
--
作者:
Wilson RD;Gunzler DD;Bennett ME;Chae J

文献摘要

被引文献

相似文献

本研究旨在确定单导联、为期 3 周的周围神经刺激 (PNS) 疗法对患有慢性偏瘫肩痛的中风幸存者减轻疼痛的功效。针对中风后患有慢性肩痛的成人的单中心、试点、随机对照试验。参与者被随机分配接受为期 3 周的单导 PNS 治疗或常规护理 (UC)。主要结局是在基线、第 1、4、12 和 16 周测量的上周最严重的疼痛(简要疼痛清单,简式问题 3)。次要结局包括疼痛干扰(简明疼痛清单,简式问题 9),通过 ShoulderQ 视觉图形评定量表测量的疼痛;和健康相关的生活质量(SF-36v2)。招募了 25 名参与者,其中 13 名参加 PNS,12 名参加 UC。与对照组相比,PNS 组疼痛明显减轻,治疗后 6 周和 12 周有显着差异。 PNS 和 UC 均与疼痛干扰和身体健康相关的生活质量的显着改善相关。短期 PNS 是治疗肩痛的安全有效的方法。与 UC 相比,疼痛减轻幅度更大,并且治疗后疼痛持续至少 12 周。
This study seeks to establish the efficacy of single-lead, 3-week peripheral nerve stimulation (PNS) therapy for pain reduction in stroke survivors with chronic hemiplegic shoulder pain. Single-site, pilot, randomized controlled trial for adults with chronic shoulder pain after stroke. Participants were randomized to receive a 3-week treatment of single-lead PNS or usual care (UC). The primary outcome was the worst pain in the last week (Brief Pain Inventory, Short Form question 3) measured at baseline, and weeks 1,4, 12, and 16. Secondary outcomes included pain interference (Brief Pain Inventory, Short Form question 9), pain measured by the ShoulderQ Visual Graphic Rating Scales; and health-related quality of life (SF-36v2). Twenty-five participants were recruited, 13 to PNS and 12 to UC. There was a significantly greater reduction in pain for the PNS group compared to controls, with significant differences at 6 and 12 weeks after treatment. Both PNS and UC were associated with significant improvements in pain interference and physical health related quality of life. Short-term PNS is a safe and efficacious treatment for shoulder pain. Pain reduction is greater than compared to UC and is maintained for at least 12 weeks after treatment.